Mizuho lowered the firm’s price target on Biogen (BIIB) to $169 from $207 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q1 report. It reduced peak Leqembi sales numbers to reflect the “slow” launch. Biogen shares have “seemingly entered value territory,” the analyst tells investors in a research note.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target lowered to $175 from $185 at JPMorgan
- Biogen’s Hold Rating: Balancing New Drug Growth with Declining MS Franchise and Safety Concerns
- Biogen’s International Growth and Promising Pipeline Drive Buy Rating
- Biogen price target lowered to $205 from $255 at Oppenheimer
- Biogen price target lowered to $205 from $217 at RBC Capital